Losmapimod

Synonyms: 洛批莫德; GSK-AHAB; GW856553X; SB856553
Losmapimod (GSK-AHAB; GW856553X) 是一种口服有效的 p38α/β MAPK 抑制剂,对 p38α 和 p38β 的 pKi 值分别为 8.1 和 7.6,它可降低 DUX4 表达从而对面肩肱型肌营养不良症有效,通过抑制 MAPK/NF-κB 减少癫痫样海马神经元的细胞凋亡 (apoptosis) 并具有抗异常性疼痛和抗热痛觉过敏作用,还能阻断拉沙热病毒 (LASV) 的进入与融合、克服非小细胞肺癌 (NSCLC) 酪氨酸激酶抑制剂耐药,并可抑制心肌衰老与炎症而具有心脏毒性保护活性。
产品编号: MS-M49778 纯度: 99.94% CAS No.: 585543-15-3 分子式: C22H26FN3O2 分子量: 383.46
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Losmapimod (GSK-AHAB; GW856553X) 是一种口服有效的 p38α/β MAPK 抑制剂,对 p38α 和 p38β 的 pKi 值分别为 8.1 和 7.6,它可降低 DUX4 表达从而对面肩肱型肌营养不良症有效,通过抑制 MAPK/NF-κB 减少癫痫样海马神经元的细胞凋亡 (apoptosis) 并具有抗异常性疼痛和抗热痛觉过敏作用,还能阻断拉沙热病毒 (LASV) 的进入与融合、克服非小细胞肺癌 (NSCLC) 酪氨酸激酶抑制剂耐药,并可抑制心肌衰老与炎症而具有心脏毒性保护活性。

生物实验数据

生物活性 Losmapimod (GSK-AHAB; GW856553X) is an orally active p38α/β MAPK inhibitor with pKi values of 8.1 and 7.6 for p38α and p38β, respectively, that reduces DUX4 expression to be effective against facioscapulohumeral muscular dystrophy, decreases apoptosis in epileptiform hippocampal neurons by inhibiting MAPK/NF-κB and exhibits anti-allodynic and anti-thermal hyperalgesic effects, blocks Lassa fever virus (LASV) entry and fusion, overcomes tyrosine kinase inhibitor resistance in non-small cell lung cancer (NSCLC), and inhibits myocardial senescence and inflammation with cardioprotective activity.
IC50 & Target p38α:8.1(pKi), p38β:7.6(pKi)
体外研究
(In Vitro)

Losmapimod (0.1-10 μM; 48.25 h) 可强效抑制 HEK293T 细胞中 LASV-GP (Josiah 株)/HIV-luc 假病毒的感染,其 EC50 为 3.68 μM。
Losmapimod (0.02-50 μM; 73 h) 可有效抑制 Vero E6 细胞中天然 LASV (Josiah 毒株) 的感染,其 EC50 值分别为 2.18 μM (TCID50 法) 和 0.71 μM (RT-qPCR 法)。
Losmapimod (30 μM; 48.25 h) 可抑制 HEK293T 细胞中四种不同 LASV 谱系来源的 LASV-GP/HIV-luc 假病毒感染,其 EC50 值范围为 0.9 μM 至 2.7 μM。
Losmapimod (30 μM) 仅在病毒附着后的融合阶段阻断 LASV-GP (Josiah 株)/HIV-luc 假病毒对 U-87 MG 细胞的感染。
Losmapimod (10 μM) 可在 pH 处理前加入时,特异性抑制 HEK293T 细胞中由低 pH 触发的 LASV-GP (Josiah 毒株) 介导的细胞-细胞融合。
Losmapimod (3-30 μM) 可剂量依赖性地抑制 LASV-GP (Josiah 株) 介导的共培养 HEK293T 与 U-87 MG 细胞间的细胞融合,在低至 3 μM 的浓度下即可观察到显著抑制作用。
Losmapimod (0.3-30 μM; 48.25 h) 可通过靶向 SSP-GP2 界面抑制 HEK293T 细胞中 LASV-GP (Josiah 株)/HIV-luc 假病毒的感染;由于针对 LASV SSP 和跨膜结构域被 LCMV 序列替换的假病毒,该化合物无抑制活性。
Losmapimod (1 μM; 24 h) 与 1 μM gefitinib 联用时,可消除吉非替尼 (Gefitinib) (MS-R64130) 耐药的人肺腺癌细胞 HCC827GR 和 H1975 中吉非替尼诱导的四倍体化。
Losmapimod (1 μM; 10-24 h) 与 1 μM 吉非替尼联用时,可抑制吉非替尼诱导的 p38 MAPK-STAT3 通路激活,以及随后在吉非替尼耐药的 HCC827GR 和 H1975 人肺腺癌细胞中 p21 和 cyclin D1 的上调。
Losmapimod (1 μM; 3 weeks) 与 1 μM 吉非替尼联合使用可显著抑制吉非替尼耐药的 HCC827GR 和 H1975 人肺腺癌细胞的锚定非依赖性生长。
Losmapimod (1 μM; 72 h) 与 1 μM 吉非替尼联合可协同降低吉非替尼耐药性人肺腺癌细胞 HCC827GR (联合指数 0.14) 和 H1975 (联合指数 0.22) 的存活率。
Losmapimod (1 μM; 3 h) 可减少癫痫样变人海马神经元的细胞凋亡,抑制 MAPK/NF-κB 信号通路的激活,并抑制炎症因子的产生,且对正常人海马神经元无有害作用。

Cell Cycle Analysis

Cell Line: gefitinib-resistant HCC827GR and H1975 human lung adenocarcinoma cells
Concentration: 1 μM (in combination with 1 μM Gefitinib)
Incubation Time: 24 h
Result: Eliminated gefitinib-induced tetraploidization, as measured by the disappearance of the tetraploid (G1) cell subpopulation in flow cytometry analysis.

Western Blot Analysis

Cell Line: gefitinib-resistant HCC827GR and H1975 human lung adenocarcinoma cells
Concentration: 1 μM (either alone or in combination with 1 μM Gefitinib)
Incubation Time: 2 h, 6 h, 10 h, 24 h
Result: Inhibited gefitinib-induced phosphorylation of p38 MAPK at 10 h in both cell lines.
Did not alter gefitinib-induced phosphorylation of YAP at 2 h or MKK3/6 at 6 h, and further up-regulated gefitinib-induced MKK3/6 phosphorylation.
Inhibited gefitinib-induced phosphorylation of STAT3 at 10 h, as well as gefitinib-induced up-regulation of p21 at 10 h and cyclin D1 at 24 h in both cell lines.

Cell Viability Assay

Cell Line: gefitinib-resistant HCC827GR and H1975 human lung adenocarcinoma cells
Concentration: 1 μM (in combination with 1 μM gefitinib)
Incubation Time: 72 h
Result: Reduced cell viability to approximately 75% in HCC827GR cells and approximately 70% in H1975 cells, while losmapimod or gefitinib alone had no inhibitory effect.
Synergistically inhibited cell proliferation with a combination index of 0.14 for HCC827GR cells and 0.22 for H1975 cells.

Apoptosis Analysis

Cell Line: human hippocampal neurons
Concentration: 1 μM
Incubation Time: 3 h
Result: Reduced the apoptosis rate of epileptiform human hippocampal neurons from ~17% to ~8%.
Reversed the upregulation of Bax and cleaved caspase 3, and the downregulation of Bcl-2 in epileptiform neurons.
Inhibited the increased phosphorylation of p38 and IκB, and restored reduced IκB expression in epileptiform neurons.
Suppressed the elevated levels of TNF-α, IL-1β, IL-6, IL-10, and CRP in epileptiform neurons.
Showed no significant effect on normal neurons.
体内研究
(In Vivo)

Losmapimod (12 mg/kg/天;口服;共 6 周) 可通过抑制 p38 MAPK 活化,改善雄性 C57BL/6 N 小鼠体内 Doxorubicin (HY-15142A) 诱导的慢性心脏功能障碍,减轻衰老与心脏炎症,并上调线粒体融合相关基因的表达。
Losmapimod (腹腔注射,1.8 mg/kg,每日 1 次,连续 3 天) 可通过抑制 MAPK/NF-κB 通路激活、减少神经元凋亡与炎症反应、恢复突触受体表达、改善癫痫发作指标并逆转认知障碍,对 Pilocarpine (MS-U99376) 诱导的 Sprague-Dawley 大鼠癫痫发挥保护作用。
Losmapimod (2-50 mg/kg;口服;每日 1 次;共 2 天) 在角叉菜胶诱导的急性疼痛模型中产生剂量依赖性的抗异常痛觉和抗痛觉过敏作用,其中机械性异常痛觉的 ED50 为 6.8 mg/kg,热痛觉过敏的 ED50 为 3.4 mg/kg,同时可抑制早期神经元和小胶质细胞的 p38 活化。
Losmapimod (30 mg/kg;口服;每日 1 次;共 2 天) 在足底切口诱导的术后疼痛模型中可产生显著的镇痛作用。

Animal Model: C57BL/6N (male, 4 weeks old, acclimated for 1 week prior to study, chronic doxorubicin-induced cardiotoxicity model)
Dosage: 12 mg/kg/day
Administration: p.o.; continuous; 4 days pre-doxorubicin plus 6-week doxorubicin treatment period
Result: Attenuated doxorubicin-induced reduction in left ventricular ejection fraction, fractional shortening, and heart rate.
Mitigated doxorubicin-induced upregulation of cardiac Nppb (brain natriuretic peptide) gene expression.
Abrogated doxorubicin-induced upregulation of the senescence marker p21^Cip1 in both heart and liver tissue.
Reduced doxorubicin-induced upregulation of cardiac Il-1α and Il-6 gene expression.
Decreased serum IL-6 and CXCL1 levels in both saline- and doxorubicin-treated mice compared to control diet groups.
Significantly upregulated cardiac mitofusin2 (Mfn2) gene expression in both saline- and doxorubicin-treated mice.
Attenuated p38 MAPK activation in both heart and liver tissue of saline- and doxorubicin-treated mice.
Increased JNK activation in heart and liver tissue of saline-treated mice; doxorubicin reduced this effect in the liver but not the heart.
No significant effect on doxorubicin-induced cardiac atrophy (heart weight/tibia length ratio).
Animal Model: Sprague-Dawley (adult male, 6-8 weeks old, 180-220 g, epilepsy induced by subcutaneous methylscopolamine pre-treatment followed by intraperitoneal pilocarpine injections to induce status epilepticus)
Dosage: 1.8 mg/kg
Administration: i.p.; once daily; 3 days
Result: Increased Nissl-positive cell count in the hippocampal CA3 region from ~170 to ~230.
Decreased hippocampal neuron apoptosis rate from ~17% to ~10%.
Reversed SE-induced upregulation of Bax and cleaved caspase-3, and downregulation of Bcl-2.
Reduced SE-induced increases in p-p38 and p-IκB protein expression, and restored IκB protein levels.
Reduced SE-induced upregulation of IL-6, TNF-α, IL-1β, IL-10, and CRP in hippocampal tissue.
Partly reversed SE-induced upregulation of NMDAR subunits (NR1A, NR2A, NR2B, NR2C, NR2D) and AMPAR GRIA2 subunit gene expression.
Increased incubation period of clonic cramp to 92.8 s, transition time to 40.1 s, and incubation period of tetanic convulsion to 126.9 s.
Reduced rate of tetanic convulsions from ~100% to ~65%.
Reduced mean escape latency and mean path length in the Morris water maze.
Increased time spent in the target quadrant and number of platform crossings compared to SE alone rats.
Animal Model: Sprague-Dawley (male, 280-300 g, acute pain model via 3% carrageenan subcutaneous injection in left hind paw)
Dosage: 2 mg/kg; 4 mg/kg; 12 mg/kg; 50 mg/kg
Administration: p.o.; once daily; Day 0 to Day 2
Result: Reversed carrageenan-induced mechanical allodynia and thermal hyperalgesia with efficacy similar to morphine at 12 mg/kg.
Reached an ED64 for mechanical allodynia and ED78 for thermal hyperalgesia at 12 mg/kg.
Yielded an ED50 of 6.8 mg/kg for mechanical allodynia and 3.4 mg/kg for thermal hyperalgesia from dose-response curve.
Significantly increased paw withdrawal thresholds to mechanical and thermal stimulation compared to baseline.
Reduced the percentage of activated p-p38-expressing DRG neurones from 90% to 50% at 2 hours after carrageenan injection.
Reduced the number of activated p-p38-expressing ipsilateral spinal cord microglial cells from 43 to 20 at 15 hours after carrageenan injection.
Showed no effect on astrocytic activation at any time point.
Animal Model: Sprague-Dawley (male, 280-300 g, postoperative pain model via plantar incision)
Dosage: 30 mg/kg
Administration: p.o.; once daily; Day 0 to Day 2
Result: Significantly reversed plantar incision-induced allodynia and hyperalgesia, enhancing paw withdrawal thresholds compared to incision-only controls.
性状 固体
颜色 White to off-white

化学信息

分子量 383.46
分子式 C22H26FN3O2
CAS No. 585543-15-3
别名 洛批莫德; GSK-AHAB; GW856553X; SB856553

储存&溶解度

体内实验配方
10% DMSO+90% Saline: < 10 mg/mL (26.08 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (26.08 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

Ethanol 中的溶解度 : 33.33 mg/mL (86.92 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
Ethanol1 mM2.6078 mL13.0392 mL26.0783 mL65.1958 mL
5 mM0.5216 mL2.6078 mL5.2157 mL13.0392 mL
10 mM0.2608 mL1.3039 mL2.6078 mL6.5196 mL
15 mM0.1739 mL0.8693 mL1.7386 mL4.3464 mL
20 mM0.1304 mL0.6520 mL1.3039 mL3.2598 mL
25 mM0.1043 mL0.5216 mL1.0431 mL2.6078 mL
30 mM0.0869 mL0.4346 mL0.8693 mL2.1732 mL
40 mM0.0652 mL0.3260 mL0.6520 mL1.6299 mL
50 mM0.0522 mL0.2608 mL0.5216 mL1.3039 mL
60 mM0.0435 mL0.2173 mL0.4346 mL1.0866 mL
80 mM0.0326 mL0.1630 mL0.3260 mL0.8149 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础